Excellent
Aligned
Patient Risk:
Low
Summary
The AI claim accurately reflects the FDA label text in Warnings and Precautions sections 5.1 and 5.3, including the stated thrombotic/stroke risk with premature discontinuation and the neuraxial/spinal puncture-related risk of epidural/spinal hematoma potentially causing long-term or permanent paralysis.
Category Scores
Accurate Statements
The label warns that discontinuing ELIQUIS prematurely increases the risk of thrombotic events (including stroke).
Supported by SECTION 5.1 (Increased Risk of Thrombotic Events after Premature Discontinuation).
The label warns that neuraxial anesthesia/spinal puncture can cause epidural/spinal hematoma potentially leading to long-term or permanent paralysis.
Supported by SECTION 5.3 (Spinal/Epidural Anesthesia or Puncture).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are directly supported by the label warnings and do not introduce unsubstantiated or contradictory safety claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Aligned
Primary Issue
Suggested Improvement